CA2748392C - Use of interleukin-22 for the prevention and/or treatment of multiple organ dysfunction syndrome (mods) - Google Patents

Use of interleukin-22 for the prevention and/or treatment of multiple organ dysfunction syndrome (mods) Download PDF

Info

Publication number
CA2748392C
CA2748392C CA2748392A CA2748392A CA2748392C CA 2748392 C CA2748392 C CA 2748392C CA 2748392 A CA2748392 A CA 2748392A CA 2748392 A CA2748392 A CA 2748392A CA 2748392 C CA2748392 C CA 2748392C
Authority
CA
Canada
Prior art keywords
multiple organ
treatment
organ dysfunction
mods
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2748392A
Other languages
English (en)
French (fr)
Other versions
CA2748392A1 (en
Inventor
Yu Liang Huang
Zhi Hua Huang
Qi Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evive Biotechnology Shanghai Ltd
Original Assignee
Generon Shanghai Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generon Shanghai Corp Ltd filed Critical Generon Shanghai Corp Ltd
Publication of CA2748392A1 publication Critical patent/CA2748392A1/en
Application granted granted Critical
Publication of CA2748392C publication Critical patent/CA2748392C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2748392A 2009-01-12 2010-01-11 Use of interleukin-22 for the prevention and/or treatment of multiple organ dysfunction syndrome (mods) Active CA2748392C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14413409P 2009-01-12 2009-01-12
US61/144,134 2009-01-12
PCT/US2010/020673 WO2010081112A1 (en) 2009-01-12 2010-01-11 Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22

Publications (2)

Publication Number Publication Date
CA2748392A1 CA2748392A1 (en) 2010-07-15
CA2748392C true CA2748392C (en) 2017-06-27

Family

ID=42316862

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2748392A Active CA2748392C (en) 2009-01-12 2010-01-11 Use of interleukin-22 for the prevention and/or treatment of multiple organ dysfunction syndrome (mods)

Country Status (7)

Country Link
US (1) US8956605B2 (https=)
EP (1) EP2385841B1 (https=)
JP (1) JP5981141B2 (https=)
CN (1) CN102348463B (https=)
AU (1) AU2010203446B2 (https=)
CA (1) CA2748392C (https=)
WO (1) WO2010081112A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
EP3385277A1 (en) 2013-03-15 2018-10-10 F. Hoffmann-La Roche AG Il-22 polypeptides and il-22 fc fusion proteins and methods of use
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
EP4106794A4 (en) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd METHOD FOR TREATING TRANSPLANT AND HOST DISEASE
CN112007146A (zh) * 2020-09-03 2020-12-01 上海市儿童医院 Il-22在治疗和/或预防脓毒症诱发的肝脏损伤的药物中的用途
US20240033232A1 (en) * 2021-03-10 2024-02-01 Wen Tan New use of (R)-B2-agonists in treatment of sepsis and acute respiratory distress syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2329274A1 (en) 1998-05-29 1999-12-02 Steven M. Ruben Interleukin-21
US20010023070A1 (en) * 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
US7226591B2 (en) * 2000-05-22 2007-06-05 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
CN101219208B (zh) * 2005-01-04 2010-08-11 健能隆医药技术（上海）有限公司 白介素-22的医药用途
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
CA2652924A1 (en) * 2006-06-19 2007-12-27 Wyeth Methods of modulating il-22 and il-17
WO2008085229A2 (en) * 2006-11-15 2008-07-17 Arteriocyte Inc. Cell-based therapies for treating liver disease
CN101168049A (zh) * 2007-10-23 2008-04-30 中国人民解放军军事医学科学院基础医学研究所 白介素-22在制备治疗肝病药物中的应用及其制备方法

Also Published As

Publication number Publication date
JP2012515165A (ja) 2012-07-05
WO2010081112A1 (en) 2010-07-15
US20110268696A1 (en) 2011-11-03
EP2385841A1 (en) 2011-11-16
JP5981141B2 (ja) 2016-08-31
AU2010203446A1 (en) 2011-07-14
AU2010203446B2 (en) 2015-12-17
CN102348463B (zh) 2014-05-07
EP2385841A4 (en) 2012-12-19
CN102348463A (zh) 2012-02-08
EP2385841B1 (en) 2016-11-16
US8956605B2 (en) 2015-02-17
CA2748392A1 (en) 2010-07-15

Similar Documents

Publication Publication Date Title
CA2748392C (en) Use of interleukin-22 for the prevention and/or treatment of multiple organ dysfunction syndrome (mods)
EP2875826B1 (en) Composition for preventing or treating sepsis
US10335455B2 (en) Method for prevention or treatment of intractable inflammatory bowel disease
AU676891B2 (en) Pharmaceutical containing the P40 subunit of interleukin 12
HU229045B1 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
JP6114186B2 (ja) 組換えヒトｇ−ｃｓｆ二量体およびその神経系疾患の治療における用途
US20090227512A1 (en) Methods and compositions for treating and preventing distal bowel lesions
RU2013139651A (ru) Новые соединения, влияющие на пищевое поведение
US20170119733A1 (en) Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases
JP7163547B2 (ja) 新規ペプチドおよびその用途
JP2006505290A5 (https=)
AU2007226130B2 (en) Use of caspases for the preparation of medicaments
US20210236597A1 (en) Methods and compositions for treating and diagnosing polycystic ovary syndrome
CN108853483B (zh) 经修饰的胸腺素β4在治疗脑缺血再灌注损伤方面的用途
CN120939206A (zh) Metrnl蛋白与氯吡格雷联合治疗血栓的药物组合物及其应用
US20040110696A1 (en) Gene therapy system and method using alpha-msh and its derivatives
JP2001192396A (ja) インターフェロン−γの活性を有するタンパク質の高純度製造法、イヌインターフェロン−γの活性を有する高純度タンパク質、イヌ疾病の治療剤およびイヌ疾病の治療方法
AU2001257420A1 (en) A gene therapy system and method using alpha-MSH and its derivatives
WO2001080877A1 (en) Preventives for reinfection after liver transplantation

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141002

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251020

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260226